HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14). At week 96, 27% of patients on alendronate versus 96% of controls presented with osteoporosis. Spine bone mineral density (BMD) increases were detected at week 48, and progressed thereafter. Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
hiv-1-associated osteoporosis
8
reversal hiv-1-associated
4
osteoporosis
4
osteoporosis once-weekly
4
alendronate
4
once-weekly alendronate
4
alendronate hiv-1-infected
4
hiv-1-infected patients
4
patients osteoporosis
4
osteoporosis randomly
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!